Bone Abstracts

Previous issue | Volume 5 | ECTS2016 | Next issue

43rd Annual European Calcified Tissue Society Congress

Rome, Italy
14 May 2016 - 17 May 2016

Oral Communications

Bone mass and bone strength Wnt signalling

Previous section
Clinical trials and osteoporosis treatment

Table of contents

Next section
Clinical trials, FGF-23 and focal osteoporosis

ba0005oc2.1 | Bone mass and bone strength Wnt signalling

Targeted deletion of Wnt1 in mesenchymal cells results in decreased bone mass and spontaneous fractures

ba0005oc2.2 | Bone mass and bone strength Wnt signalling

Deletion of Dickkopf-1 in osteoblasts or osteocytes increases bone volume in female mice

ba0005oc2.3 | Bone mass and bone strength Wnt signalling

Life-course GWAS approach for total body BMD unveils 16 new BMD loci with some exerting age-specific effects

ba0005oc2.4 | Bone mass and bone strength Wnt signalling

Up-regulation of Wnt antagonists contributes to the attenuated response of bone formation to repeat doses of sclerostin antibody in a mouse model

ba0005oc2.5 | Bone mass and bone strength Wnt signalling

Is circulating sclerostin an endocrine modulator of bone mass?

ba0005oc2.6 | Bone mass and bone strength Wnt signalling

N-cadherin maintains osteoprogenitor number and restrains Wnt signaling in osteoblasts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more

43rd Annual European Calcified Tissue Society Congress

Bone mass and bone strength Wnt signalling

BiosciAbstracts